Literature DB >> 14631172

Otitis media: concepts and controversies.

David H Darrow1, Nariman Dash, Craig S Derkay.   

Abstract

PURPOSE OF REVIEW: Otitis media is the most common bacterial infection among children, accounting for as many as 30 million office visits annually. Proper treatment has become critical as offending pathogens become increasingly resistant to antibiotics and the cost of managing the disorder has exceeded 3 billion dollars per year. However, data suggest that many practitioners still struggle with the diagnosis of otitis media and often recommend medical and surgical intervention inappropriately. This article presents recent advances in the otitis media literature and an evidence-based approach to its management. RECENT
FINDINGS: Recent investigations have resulted in the following findings: (1) bacterial biofilms may account for the persistence of middle ear disease; (2) there is increasing evidence that heredity and reflux are risk factors for otitis media; (3) primary care providers may be receiving poor otitis media training, leading to inadequate diagnostic skills; (4) medical and surgical therapy are of limited utility in the management of acute and recurrent acute otitis media; (5) antibiotics and steroids are of limited value in the treatment of chronic middle ear effusion; (6) delayed management of effusion may not adversely affect development in children; (7) vaccination for pneumococcus may alter the serotypes responsible for otitis media; and (8) vaccine candidates for other middle ear pathogens are under investigation.
SUMMARY: Management of otitis media is constantly evolving, based on research from a variety of medical subspecialties. It is incumbent on the otolaryngologist and primary care providers treating otitis media to keep pace with and synthesize these findings into a rational approach to treatment.

Entities:  

Mesh:

Year:  2003        PMID: 14631172     DOI: 10.1097/00020840-200312000-00002

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  7 in total

1.  Regeneration of chronic tympanic membrane perforation using an EGF-releasing chitosan patch.

Authors:  Hoon Seonwoo; Seung Won Kim; Jangho Kim; Tian Chunjie; Ki Taek Lim; Yeon Ju Kim; Shambhavi Pandey; Pill-Hoon Choung; Yun-Hoon Choung; Jong Hoon Chung
Journal:  Tissue Eng Part A       Date:  2013-09       Impact factor: 3.845

2.  Use of the chinchilla model for nasopharyngeal colonization to study gene expression by Moraxella catarrhalis.

Authors:  Todd C Hoopman; Wei Liu; Stephanie N Joslin; Christine Pybus; Jennifer L Sedillo; Maria Labandeira-Rey; Cassie A Laurence; Wei Wang; James A Richardson; Lauren O Bakaletz; Eric J Hansen
Journal:  Infect Immun       Date:  2011-12-19       Impact factor: 3.441

3.  Mutation in Phex gene predisposes BALB/c-Phex(Hyp-Duk)/Y mice to otitis media.

Authors:  Fengchan Han; Heping Yu; Ping Li; Jiangping Zhang; Cong Tian; Hongbo Li; Qing Yin Zheng
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

4.  Effect of glucocorticoids on aquaporin-1 in guinea pigs with otitis media with effusion.

Authors:  Chenjie Yu; Xinyan Cui; Feng Chen; Jun Yang; Xiaoyun Qian; Xia Gao
Journal:  Exp Ther Med       Date:  2013-04-02       Impact factor: 2.447

5.  Fisetin administration improves LPS-induced acute otitis media in mouse in vivo.

Authors:  Peng Li; Dan Chen; Yang Huang
Journal:  Int J Mol Med       Date:  2018-03-22       Impact factor: 4.101

6.  Quercetin inhibits NTHi-triggered CXCR4 activation through suppressing IKKα/NF-κB and MAPK signaling pathways in otitis media.

Authors:  Yu-Kun Ma; Yu-Bin Chen; Peng Li
Journal:  Int J Mol Med       Date:  2018-03-20       Impact factor: 4.101

7.  NOD2/RICK-dependent β-defensin 2 regulation is protective for nontypeable Haemophilus influenzae-induced middle ear infection.

Authors:  Jeong-Im Woo; Sejo Oh; Paul Webster; Yoo Jin Lee; David J Lim; Sung K Moon
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.